Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlzeCure Pharma ABFRA:AC6 -13.18%33 3-Year EBITDA Growth Rate is 22.20% as of Mar. 2026, which is 74% above its 10-year median of 12.75. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, AlzeCure Pharma AB ranks better than 58.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of AlzeCure Pharma AB was 37.60% per year. The lowest was -46.60% per year. And the median was 12.75% per year.
AlzeCure Pharma AB (FRA:AC6) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AlzeCure Pharma AB 3-Year EBITDA Growth Rate Related Terms
FRA:AC6 vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, AlzeCure Pharma AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AlzeCure Pharma AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AlzeCure Pharma AB's 3-Year EBITDA Growth Rate falls into.
AlzeCure Pharma AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.20% mean?
AlzeCure Pharma AB (FRA:AC6) has a 3-Year EBITDA Growth Rate of 22.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AlzeCure Pharma AB and its competitors. This is 74% above median its historical median of 12.75. According to the industry distribution chart, AlzeCure Pharma AB ranks #466 out of 1130 companies in the Biotechnology industry, placing it in the top 41.2%.
Is AlzeCure Pharma AB's 3-Year EBITDA Growth Rate too high?
AlzeCure Pharma AB's current 3-Year EBITDA Growth Rate of 22.20% is 74% above median its 10-year median of 12.75. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. AlzeCure Pharma AB's value of 22.20% is 49.5% above this industry median. Based on the distribution chart, AlzeCure Pharma AB ranks #466 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AlzeCure Pharma AB ranks #466 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts AlzeCure Pharma AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. AlzeCure Pharma AB's value of 22.20% is 49.5% above this benchmark. While the company's 10-year median is 12.75 vs. the industry median of 14.85, AlzeCure Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AlzeCure Pharma AB's current 3-Year EBITDA Growth Rate of 22.20% is 49.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AlzeCure Pharma AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AlzeCure Pharma AB's current 3-Year EBITDA Growth Rate is 22.20%, which is 74% above median its own 10-year median of 12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current 3-Year EBITDA Growth Rate of 22.20%. The current 3-Year EBITDA Growth Rate is 22.20%, which is 74% above median its 10-year median of 12.75 and 49.5% above the Biotechnology industry median of 14.85. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current 3-Year EBITDA Growth Rate is 22.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score
Get the complete analysis for FRA:AC6
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AC6 has been successfully added to your 
